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RESEARCH ARTICLE
Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin
Emily Wenandea,b , Uffe H. Olesena , Malene R. Boesenc, Daniel P. Perssond , Catharina M. Lerchea ,
Stefan St€urupc , Bente Gammelgaardc , Søren Hustedd , R. Rox Andersonb and Merete Haedersdala,b
aDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen NV, Denmark; bWellman Center for
Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; cDepartment of Pharmacy, Faculty of
Health and Medical Sciences, University of Copenhagen, Copenhagen Ø, Denmark; dDepartment of Plant and Environmental Sciences,
Faculty of Science, University of Copenhagen, Frederiksberg C, Denmark
ABSTRACT
Systemic chemotherapy with the anticancer agent cisplatin is approved for advanced non-melanoma
skin cancer (NMSC), but topical treatment is limited by insufficient cutaneous penetration. We studied
the impact of ablative fractional laser (AFL) exposure on topical cisplatin’s pharmacokinetics and bio-
distribution in skin, using microscopic ablation zones reaching the mid- (MAZ-MD; 620lm depth) and
deep dermis (MAZ-DD; 912lm depth) (k¼ 10,600nm, 196 MAZ/cm2). Assessed in an in vitro Franz cell
model after 0.5-, 4-, 24 h topical exposure (n¼ 8), cisplatin delivery was greatly accelerated by AFL,
shown by quantitative- and imaging-based inductively coupled plasma-mass spectrometry (ICP-MS).
After 30minutes, cisplatin concentrations were 91.5, 90.8 and 37.8lg/cm3 in specific 100-, 500, and
1500lm skin layers respectively, contrasting to 8.08, 3.12, 0.64lg/cm3 in non-laser-exposed control
skin (p< .001; control vs MAZ-MD). Supported by element bioimaging, the greatest relative increases
occurred in the deep skin compartment and at later time points. After 24 h, cisplatin concentrations
thus rose to 1829, 1732 and 773lg/cm3, representing a 25-, 103- and 447-fold enhancement in the
100, 500, and 1500lm deep skin layers versus corresponding controls (p< .001; MAZ-MD). A signifi-
cant difference in cutaneous uptake using MAZ-MD and MAZ-DD was not shown at any time point,
though deeper laser channels resulted in increased transdermal cisplatin permeation (p .015). In con-
clusion, AFL is a rapid, practical and existing skin treatment that may provide greatly enhanced uptake
of topical cisplatin for treatment of superficial and deep skin cancer.
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Introduction
Since its approval in 1978, cisplatin (300.1 g/mol) has
remained one of the most successful and versatile anticancer
agents in oncology. Used as both mono- and combination
therapy, the drug represents a cornerstone treatment of epi-
thelial cancers of the head and neck, lungs, testes, ovaries
and bladder (Chabner et al., 2015). On the molecular level,
cisplatin is first activated by hydrolysis inside the cell, subse-
quently forming intra- and interstrand crosslinks with DNA.
The resulting distortion in DNA structure leads to G2/M cell
cycle arrest, inhibition of replication, transcription and ultim-
ately, cellular apoptosis (Chabner et al., 2015).
The activity of cisplatin against non-melanoma skin cancer
(NMSC) is established in both preclinical and clinical settings.
Cisplatin causes lethality in multiple NMSC cell lines
(Featherstone et al., 1991, Gil et al., 2016, Olesen et al.,
2017), and systemic cisplatin-based chemotherapy is conven-
tionally used for both locally-advanced and metastatic NMSC
(Moeholt et al., 1996, Bejar & Maubec, 2014, Trodello et al.,
2017). The agent’s usefulness is however offset by notable
toxicity following intravenous administration (Chabner et al.,
2015, Chang et al., 2018). An effective treatment using
topical cisplatin would be far less toxic, but is limited by
insufficient penetration into the skin likely due to the agents’
poor lipophilicity (reported range of experimental LogP: -2.55
 -2.19) (Leo et al., 1995, Ghezzi et al., 2004).
Local delivery strategies have the potential to maximize
target effects while sparing off-target tissue (Marwah et al.,
2016). Efforts to develop topical cisplatin-based therapies
have prompted the application of multiple enhancement
techniques, including chemo-coated microneedles, ionto-
phoresis, intralesional depot injection, electrochemotherapy,
cisplatin bead implantation and a range of chemical
enhancers (Chang et al., 1993, Kitchell et al., 1995, Sersa
et al., 1998, Bacro et al., 2000, Hewes & Sullins, 2006,
Simonetti et al., 2009, Gupta et al., 2014, Byrne et al., 2015,
Uddin et al., 2015). Laser-assisted drug delivery (LADD) con-
stitutes an alternative strategy that has gained clinical impact
as a practical, highly effective, and customizable cutaneous
delivery modality. By generating microscopic ablation zones
(MAZs) in the skin using an ablative fractional CO2 or erbium
laser (AFL), the skin’s natural barrier function is compromised.
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The resulting increase in cutaneous porosity improves bio-
availability of topically-applied agents. To date, use of LADD
is reported for a range of indications including neoplastic
skin lesions, though cisplatin has yet to be studied
(Haedersdal et al., 2016, Wenande et al., 2017a).
Recently, we showed that AFL-assisted delivery provides
increased uptake of the anticancer agents 5-fluorouracil
(5-FU) and methotrexate in ex vivo skin, with greater
enhancement using deeper laser channels (Taudorf et al.,
2015, Wenande et al., 2017b). With the overall perspective to
develop a potent, local treatment strategy for NMSC using
chemotherapeutic agents, this study assesses the impact of
AFL on cutaneous uptake of cisplatin, measuring pharmaco-
kinetics and drug biodistribution using two different laser-
channel depths.
Materials & methods
Study design
Impact of AFL delivery on topical cisplatin diffusion was inves-
tigated in a total of 80 fresh frozen, full-thickness porcine skin
samples using an in vitro Franz cell (FC) model. Intervention
groups (n¼ 8) comprised skin exposed to AFL using two dif-
ferent laser-channel depths and non-laser-exposed control
skin. After 0.5, 4 or 24h topical cisplatin exposure, cutaneous
drug biodistribution was assessed in three specific skin depths
(100, 500 and 1500lm) using inductively coupled plasma-
mass spectrometry (ICP-MS). Measurement of cisplatin content
in FC receiver compartments evaluated transdermal cisplatin
permeation (Table 1, Figures 1 and 2). Laser ablation ICP-MS
(LA-ICP-MS) imaging provided semi-quantitative visualization
Table 1. Study design and ICP-MS quantification of cisplatin delivery in AFL-exposed and intact control skin.
Intervention &
time (hours) n
Cryosection depth/
sample type
Quantified platinum
(median and IQR)
(ng/ml)
Calculated cisplatin
Concentration†
(lg/cm3)
Calculated cisplatin
Concentration‡
(lg/cm2) p-value¥
Cisplatinþ intact skin
0.5 h 8 100 mm 6.10 (3.19–7.65) 8.08 (4.22–10.14) – –
500 mm 2.36 (1.75–3.24) 3.12 (2.32–4.29) – –
1500mm 0.48 (0.29–0.66) 0.64 (0.38–0.87) – –
Receiver 0.35 (0.15–1.39) – 5.5 104 –
4 h 8 100 mm 29.0 (25.0–48.8) 38.4 (33.2–64.7) – –
500 mm 3.69 (2.15–9.70) 4.88 (2.85–12.8) – –
1500mm 0.98 (0.38–2.96) 1.29 (0.50–3.93) – –
Receiver 0.42 (0.15–10.6) – 6.6 104 –
24 h 8 100 mm 55.6 (41.7–63.1) 73.8 (55.3-83.7) – –
500 mm 12.8 (6.63-21.8) 16.9 (8.79–28.9) – –
1500mm 1.31 (0.66–1.78) 1.73 (0.87–2.36) – –
Receiver 8.22 (1.83–24.6) – 0.0128 –
CisplatinþMAZ-MDa
0.5 h 8 100 mm 69.0 (64.3–85.3) 91.5 (85.2–113) – <.001
500 mm 68.5 (64.3–89.0) 90.8 (85.2–118) – <.001
1500mm 28.5 (23.3–35.3) 37.8 (30.8–46.8) – <.001
Receiver 26.0 (19.5–54.0) – 0.0406 .015
4 h 8 100 mm 338 (296–387) 449 (392–514) – .006
500 mm 349 (320–382) 463 (424–506) – .012
1500mm 147 (121–193) 195 (160–256) – .003
Receiver 1176 (599–2343) – 1.838 <.001
24 h 8 100 mm 1380 (1255–1861) 1829 (1664–2468) – <.001
500 mm 1307 (1127–1347) 1732 (1494–1786) – <.001
1500mm 583 (497–639) 773 (658–878) – <.001
Receiver 3031 (2300–5370) – 4.735 <.001
CisplatinþMAZ-DDb
0.5 h 8 100 mm 72.0 (49.0–75.3) 95.4 (65.0–99.8) – <.001
500 mm 74.5 (67.3–80.5) 98.7 (89.2–107) – <.001
1500mm 24.5 (18.5–35.8) 32.5 (24.5–47.4) – <.001
Receiver 31.5 (17.3–49.3) – 0.0492 .015
4 h 8 100 mm 247 (366–483) 568 (485–641) – <.005
500 mm 396 (345–431) 524 (457–571) – <.005
1500mm 203 (179–227) 268 (237–301) – <.005
Receiver 1348 (1106–1955) – 2.107 <.005
24 h 8 100 mm 1414 (1380–1465) 1874 (1829–1942) – <.001
500 mm 1293 (1211–1565) 1713 (1606–2076) – <.001
1500mm 720 (608–863) 954 (807–1144) – <.001
Receiver 7243 (6092–10687) – 11.316 <.001
NaClþMAZ-DD
(negative control) 8 100 mm <1.00 – – –
24 h 500 mm <1.00 – – –
1500mm <1.00 – – –
Receiver <1.00 – – –
AFL: ablative fractional laser.
†Calculated based on quantified platinum and skin volume (surface area thickness), where individual skin section volume was
0.2515 cm20.003 cm.
‡Calculated based on a known receiver fluid volume and a skin surface area of 0.64 cm2.
¥Adjusted p-value comparing cisplatin uptake in AFL-exposed samples and non-laser exposed controls at corresponding time points.
alaser delivery via microscopic ablation zones reaching the mid-dermis (MAZ-MD; 620mm).
blaser delivery via microscopic ablation zones reaching the deep dermis (MAZ-DD; 912mm).
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Figure 1. Impact of ablative fractional laser (AFL) delivery on intracutaneous cisplatin biodistribution at skin depths of (A) 100 lm, (B) 500 lm and (C) 1500 lm as
well as (D) transdermal cisplatin permeation versus non-laser-exposed controls. Concentrations are presented as medians with interquartile ranges. Compared to
control samples, AFL-treated skin with microscopic ablation zones reaching the mid- (MAZ-MD) and deep dermis (MAZ-DD) showed statistically significant ()
enhanced drug uptake in all examined skin layers, culminating at 24 h. In the deepest skin compartment, deposition increased steadily, fitted to power regression
models for both laser channel depths (MAZ-DD: cisplatin1500lm (lg/cm
3)¼ 65.103  time(h)0.875; R2¼ 0.957; MAZ-MD: cisplatin1500lm (lg/cm3)¼ 65.520 time(h)0.775; R2¼ 0.973). Increasing laser channel depth did not significantly affect degree of cisplatin delivery in any skin layer. On the other hand, transdermal
permeation was found to be significantly greater (†) using deeper channels after 24-h cisplatin diffusion (MAZ-MD vs MAZ-DD, p¼ .001).
Figure 2. Schematic illustration of relative enhancements in cisplatin deposition within specific skin layers using microscopic ablation zones reaching the mid- and
deep dermis compared to non-laser exposed skin (MAZ-MD: 620 lm; MAZ-DD: 912 lm). Overall, impact of laser-assisted cisplatin delivery was most pronounced in
deep skin layers and at later time points, resulting in a maximum 552-fold enhancement by 24 h in the 1500 mm skin compartment (control skin vs MAZ-DD,
p¼ .001). Cutaneous cisplatin concentrations provided by MAZ-MD and MAZ-DD were not significantly different (p .084), although a tendency to greater deep
drug delivery by MAZ-DD was observed at later time points.
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of cisplatin kinetics and biodistribution in selected MAZ-DD
and control samples (Figure 3).
Skin preparation
Immediately after euthanasia, full-thickness skin from the
flank of one female Danish Landrace pig (3months, 34 kg)
was surgically excised. Skin was stored for up to twenty days
at -80 C and thawed to room temperature at study initi-
ation. During preparation, excessive hairs and subcutaneous
fat were removed using an electric trimmer and scalpel,
respectively. Care was taken to avoid nicking or scraping the
skin surface.
Laser irradiation and channel dimensions
AFL was performed using an Ultrapulse CO2 laser DeepFx
handpiece (k¼ 10,600 nm, Lumenis, Santa Clara, CA, USA) at
0.12mm spot size, 5% density (196 MAZ/cm2) and pulse
energies of 25mJ/microbeam (mJ/mb) or 50mJ/mb. This cre-
ated an array of MAZs extending to the mid-dermis (MAZ-
MD) and deep dermis (MAZ-DD) respectively, determined by
blinded measurement of distinct channels in histological
cross-sections (n¼ 10). Median MAZ-MD and -DD depths
were 620 mm (interquartile range (IQR) 570-689mm) and
912mm (840–1063 mm), while corresponding surface ablation
widths were 108mm (98–126 mm) and 130 mm (121–141 mm),
respectively. Coagulation zone (CZ) thicknesses along the
margins of MAZs, were 46 mm (41–49 mm) and 51 mm
(46–54 mm). Total ablated volume of 196 MAZs/cm2 was cal-
culated based on the volume of a cone (1=3 p (1=2width
[cm])2 depth [cm] number of MAZs/cm2), resulting in
37.1 105 cm3/cm2 skin area for MAZ-MD and
79.8 105 cm3/cm2 skin area for MAZ-DD.
Franz cell diffusion model
Within 30minutes of laser exposure, full-thickness skin sam-
ples were mounted on a FC model (PermeGear Inc.,
Hellertown, PA, USA) consisting of a donor and receiver com-
partment. Skin sample stratum corneum (0.64 cm2) faced
donor compartments, while receiver compartments con-
tained 5.5–5.8ml phosphate buffered saline (pH 7.4, 37 C)
and a magnetic stir bar. At baseline, 1ml commercially avail-
able IV cisplatin solution (1mg/mL) (Accord Healthcare
Limited, Middlesex, UK) corresponding to 1mg cisplatin per
FC (1.56mg/cm2), was topically applied to skin samples via
donor compartments. Prior to sealing FCs with ParafilmVR
(Bemis, Oshkosh, WI, USA), skin impedance measurement
was used to confirm barrier disruption in laser-treated sam-
ples and an intact barrier in control skin (mean: 4.70 kX (AFL
skin); 58.42 kX (intact skin)) (Prep-check Electrode Impedance
Meter 30Hz, General Devices, Ridgefield, NJ, USA).
At 0.5, 4 or 24 h diffusion time, skin samples were dis-
mounted, padded dry, and biopsied using an 8-mm punch
(0.503 cm2 surface area). A biopsy half from each sample was
then mounted on Tissue TekVRO.C.TTM Compound (Sakura
Finetek Europe B.V., Alpehn aan den Rijn, Netherlands), snap
frozen, cut in 30 mm en face cryosections at a skin depths of
100, 500 and 1500 mm (±20mm) and stored at 80 C.
Illustrating cutaneous cisplatin biodistribution, drug depos-
ition in depth-specific cryosections was analyzed using ICP-
MS. Receiver fluid was collected for ICP-MS quantification of
cisplatin permeation through skin.
Drug quantification: inductively coupled plasma-mass
spectrometry (ICP-MS)
Prior to ICP-MS, individual cryosections were transferred to
glass vials and dissolved in distilled 65% HNO3 for 6 hrs at
Figure 3. Visualization of cutaneous cisplatin biodistribution with and without laser delivery (MAZ-DD), imaged by laser ablation inductively coupled plasma-mass
spectrometry (LA-ICP-MS) in bisected samples (superficial skin layers appear medially in images). Cisplatin biodistribution is presented normalized against endogen-
ous 13C. To further show relative skin distribution in individual samples, an internal normalization was used where the highest cisplatin detection points in each
sample was set to an index of 100 (see scale bar). Remaining data points were then multiplied with the same correction factor. AFL delivery led to accelerated and
enhanced cisplatin deposition within 30minutes of topical drug application, with progressively greater and deeper uptake over time. Reaching maximal delivery at
24 hours, substantial drug detection was noted extending to the deepest layers of skin AFL samples. In contrast in non-laser-exposed samples, cisplatin remained
confined to the outermost skin layers despite topical exposure for 24 h.
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room temperature, followed by 30% H2O2 overnight. Before
analysis, mixtures underwent successive dilution with acid mix
(0.65% HNO3: 1% HCl). Platinum concentrations (
194Ptþ and
195Ptþ) were measured on an ICP-MS system (ELAN DRC-e or
ELAN 6000, PerkinElmer SCIEX, Waltham, MA, USA).
Quantification was performed applying an external standard
curve, with platinum calibration standards freshly prepared
each day (Pt concentration range: 0.1–20 ng/mL, limit of quan-
tification 0.010 ng/mL). All samples were analyzed in dupli-
cate. Measured platinum concentrations (ng/mL) were
converted to an absolute amount of cisplatin in each sample
(ng), presented as medians with corresponding IQRs. Median
cisplatin accumulation in specific skin layers was then calcu-
lated based on skin volume (area thickness;
0.2515 cm2 0.003 cm) and presented as mg/cm3.
For assessment of transdermal cisplatin permeation,
receiver fluid was evaporated to dryness (Concentrator Plus,
Eppendorf, Hamburg, Germany) and taken into solution with
0.65% HNO3: 1% HCl acid mix. Samples were centrifuged at
1,4000 rpm for 10min (Centrifuge 5430, Eppendorf,
Hamburg, Germany), underwent additional acid mix dilution
and analyzed using ICP-MS as previously described.
Transdermal permeation to receiver compartments is pre-
sented as mg/cm2, determined by the 0.64 cm2 skin surface
area over which the drug diffused.
Drug visualization: laser ablation inductively coupled
plasma-mass spectrometry (LA-ICP-MS)
Semi-quantitative visualization of cisplatin biodistribution
was performed in full-thickness MAZ-DD and non-laser
exposed skin samples after 0.5, 4 and 24 h topical drug
exposure (Figure 3). LA-ICP-MS analyses were performed
using a nanosecond LA unit (NWR193, New Wave Research,
Fremont, CA, USA) equipped with an ArF excimer laser
source operating at 193 nm as previously described (Persson
et al., 2016). Sample transfer from the ablation chamber to
the ICP-MS was improved with a Dual Concentric Injector
(DCI, New Wave Research, Fremont, CA, USA). The following
settings were used: energy: 0.5–0.6 J cm2 (20% of max-
imum energy), scan speed: 272mm s1, repetition rate: 40Hz
and spot size: 50 mm. All elemental signals were obtained
with an Agilent 7900 ICP-MS (Agilent technologies,
Manchester, UK), operated in H2-mode (3mL min
1). Sample
cone depth in the ICP-MS was 3.9mm, with carrier gas set to
0.89mL min1. Analyzed isotopes were: 13C, 39K, 56Fe, 34S
and 195Pt (Figures 3 and 4), using integration times of 0.1
(13C), 0.03 (34S), 0.02 (195Pt) and 0.01 (39K and 56Fe) seconds.
The scan cycle was 0.184 seconds. All data was processed
with SigmaPlot version 13 (Systat Software Inc., London, UK)
and normalized against the samples’ endogenous 13C. For a
relative distribution analysis of the data of each sample, an
additional internal normalization was used where the highest
data point in each sample was recalculated and set to index
100. Remaining data points were then multiplied with the
same correction factor to produce images where relative,
internal skin distribution is displayed (Figure 3).
Statistics
Descriptive statistics are presented as medians with corre-
sponding IQRs. Non-parametric statistics compared cisplatin
deposition in unpaired samples using Kruskal–Wallis and
Mann–Whitney U tests. For comparison of cisplatin deposition
in layers of the same sample, paired Friedman and Wilcoxon
tests were applied. p-values were exact, 2-sided, and deemed
statistically significant if <.05 after Bonferroni correction for
multiple comparisons. To estimate the relation between time
and AFL-assisted cisplatin uptake in the 1500mm skin com-
partment, linear, logarithmic, inverse, power, sigmoid, and
exponential mathematical models were fitted to the collected
Figure 4. LA-ICP-MS bioimaging of endogenous sulfur (34S) in MAZ-DD (above)
and non-laser exposed (below) porcine skin, normalized against 13C. Notable
34S detection is seen corresponding to hair shafts, the outermost stratum cor-
neum and to a lesser extent, the underlying epidermal layers.
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data, revealing power model regression to provide the best fit
(Figure 1). Statistical and graphical analyses were performed
using SPSS version 24 (IBM Corporation, Arnmonk, NY, USA)
and GraphPad Prism version 7.00 (GraphPad Software Inc.,
San Diego, CA, USA), respectively.
Results
Cutaneous cisplatin deposition: quantitative analysis
In non-laser-exposed skin, drug uptake was gradual and lim-
ited, with maximum uptake measured in all skin layers at
24 h (Table 1, Figure 1). Cisplatin deposition was primarily
confined to the superficial 100 mm skin compartment, with
concentrations remaining <2 mg/cm3 in the deep 1500 mm
layer throughout 0–24 hrs. Cutaneous drug biodistribution
was significantly altered by AFL pretreatment, observed con-
sistently in all skin layers. Thus, in contrast to intact skin,
concentrations in AFL-exposed samples were generally simi-
lar at 100 and 500 mm depth. Deeper deposition at 1500 mm
ranged from 41–44% (MAZ-MD) and 32–82% (MAZ-DD) of
the examined superficial layers (Table 1).
AFL greatly accelerated cutaneous cisplatin uptake. By
30minutes, AFL-assisted deposition in deep skin layers was 22-
fold greater than in intact skin that had undergone topical cis-
platin exposure for a full 24hours (MAZ-MD vs. untreated:
37.8mg/cm3 vs 1.73mg/cm3 (1500mm), p< .001). Increases were
also noted in the superficial compartments despite the short,
30-min exposure time (MAZ-MD vs. untreated (100mm):
91.5mg/cm3 (30min) vs 73.8mg/cm3 (24h) p¼ .04).
Impact of AFL delivery was both time- and skin depth-
dependent, with greatest relative enhancement in the deep-
est skin layer and at later time points (Table 1, Figure 1). At
4 h diffusion time, maximum cisplatin concentrations were
568, 524, and 268mg/cm3, reflecting a 15-, 107-, and 208-fold
enhancement versus intact skin at 100, 500, and 1500 mm
depth respectively (MAZ-DD vs untreated, p< .012) (Figure
2). By 24 hours, a 552-fold increase in maximum cisplatin
concentration was noted in the 1500 mm layer (MAZ-DD vs
untreated: 954 mg/cm3 vs 1.73 mg/cm3 (1500mm), p< .001), as
compared to lesser 25- and 101-fold enhancements in more
superficial 100 mm and 500 mm compartments (MAZ-DD vs
untreated: 1874 mg/cm3 vs 73.8mg/cm3 (100mm) p< .001;
1713mg/cm3 vs 16.9mg/cm3 (500mm), p< .001).
Increasing median laser channel depth from 620 mm
(MAZ-MD) to 912 mm (MAZ-DD) failed to provide statistically
significant enhancement in cisplatin delivery at any exam-
ined skin layer from 0 to 24 h (Table 1, Figure 1). A trend
towards increased uptake was observed at 4 h diffusion time,
where deeper laser channels provided greater cisplatin
deposition in all skin compartments, most pronounced in the
1500mm skin layer (MAZ-MD vs MAZ-DD: 449 mg/cm3 vs
568mg/cm3 (100mm), p¼ .084) (Figure 2). By 24 h, deposition
in 100 and 500 mm compartments were comparable regard-
less of laser channel depth (MAZ-MD vs MAZ-DD: 1829 mg/
cm3 vs 1874 mg/cm3 (100mm), p¼ .981). By contrast in
1500mm skin layer, a tendency towards greater uptake using
deeper laser channels remained (MAZ-MD vs MAZ-DD:
773mg/cm3 vs 954 mg/cm3, p¼ .098).
Cutaneous cisplatin deposition: bioimaging analysis
Quantitative measurements of Pt distribution by ICP-MS was
supported by LA-ICP-MS bioimaging, which revealed strik-
ingly improved intracutaneous cisplatin delivery after AFL
(Figure 3). Within 30min, cisplatin was visualized to a skin
depth of approx. 1750 mm, with maximum drug detection
corresponding to superficial layers and CZs. In the 520 mm
separating spaces between laser channels, a uniform lateral
drug distribution was observed within each skin layer.
Quantity and depth of drug detection increased progres-
sively with longer topical exposure from 0.5 to 24 h.
Reaching a maximum at 24-h, substantial AFL-assisted cis-
platin uptake was seen extending to the deepest layers of
skin samples (approx. 3750 mm). Contrastingly in unexposed
skin, 24-h topical exposure resulted in minimal drug penetra-
tion over outermost skin compartments, with cisplatin pri-
marily concentrated on the cutaneous surface.
Transdermal cisplatin permeation
AFL led to prominent increases in cisplatin permeation
(Table 1, Figure 1). For both laser channel depths, transder-
mal cisplatin was relatively similar at 30min, demonstrating
74- and 90-fold increases compared to unexposed skin
(untreated vs MAZ-MD: 0.001mg/cm2 vs 0.041 mg/cm2 p¼ .02;
vs MAZ-DD: 0.05 mg/cm2 p¼ .015). By 4 h, the degree of
enhancement using MAZ-MD and -DD had climbed to 2785-
and 3192-fold respectively, consistent with rapid drug transit
through laser-treated samples. At 24 h, permeation depended
significantly on laser channel depth (MAZ-MD vs MAZ-DD:
4.74 mg/cm2 vs 11.3mg/cm2, p¼ .001), resulting in 370-, and
884-fold cisplatin using MAZ-MD and MAZ-DD, respectively.
Discussion
A major and unsolved limitation of topical skin cancer treat-
ment, regardless of the agent applied, is inadequate cutane-
ous drug delivery (Taveira & Lopez, 2011). Aiming to address
this issue, this study showed that AFL provides enhanced
and accelerated cisplatin uptake into full-thickness skin. By
just 30min, AFL-assisted drug deposition was significantly
greater than the maximal 24-h uptake in non-laser-exposed
samples, confirmed by highly sensitive ICP-MS quantification
and -bioimaging techniques. Crucially, the greatest impact
on cisplatin uptake was observed in the deepest skin layers,
where striking enhancements of over 500-fold were noted at
1500 mm depth. Delivery by MAZ-MD and MAZ-DD was not
significantly different, although a tendency to greater deep
drug deposition using MAZ-DD was observed over time. AFL
treatment of skin is a rapid, practical, well-tolerated, as well
as available clinical procedure. Our results suggest that
AFL-assisted cisplatin delivery is a promising strategy in the
pursuit of a more effective topical treatment for NMSC.
Reports of intravenous cisplatin-based chemotherapies in
the management of unresectable NMSC predate the 1980s
(Salem et al., 1978, Guthrie et al., 1985). Today, despite the
advent of more targeted treatments particularly for basal cell
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carcinoma (BCC), cisplatin remains among the most effective
agents against advanced stages of the disease. As such, com-
plete response rates of 37% and 36–57% are reported after
systemic therapy for BCC and squamous cell carcinoma
(SCC), respectively (Moeholt et al., 1996, Bejar & Maubec,
2014). More recently, local cisplatin treatments have been
investigated in clinical and animal studies (Chang et al.,
1993, Kitchell et al., 1995, Sersa et al., 1998, Bacro et al.,
2000, Hewes & Sullins, 2006, Gupta et al., 2014). Treating two
patients with electrochemotherapy with intratumoral injec-
tion, Sersa et al. (1998) reported complete responses in 2/2
SCCs and 4/4 BCCs, 8–11months post-treatment. Using a
route more closely resembling AFL-assisted delivery, two
studies assessed topical cisplatin iontophoresis for advanced
BCC and SCC, observing 5/16 complete- and 7/16 partial
responses with best effect in BCCs, small tumors, and after
co-administration of epinephrine (Chang et al., 1993, Bacro
et al., 2000). These reports support the rationale for develop-
ing an improved topical strategy that harnesses cisplatin’s
activity against NMSC.
Threshold cisplatin concentrations for adequate NMSC cell
inhibition have yet to be described in vivo. In the in vitro set-
ting, however, a range of inhibitory concentrations are
reported for NMSC cells (Featherstone et al., 1991, Uddin
et al., 2015, Gil et al., 2016, Olesen et al., 2017). Examined in
immortalized keratinocytes (HaCaT) and multiple BCC and
SCC lines, Olesen et al. (2017) noted 24-h IC50 values of
1.8mM, 3.5–4.6mM, and 2.0–2.5 mM respectively, while
Featherstone et al. (1991) correspondingly observed
76%–96% reductions in keratinocyte viability following 24-h
cisplatin exposure at 4 and 8 mM. Measured at 1500 mm skin
depth within 30min of drug application, we observed cis-
platin skin concentrations of >100 mM. In the clinical setting,
intratumoral cisplatin concentrations are typically reported in
the range of 0.5–4.5 mg/g tissue 0–72 hours after systemic
infusion for head and neck SCC, assuming a skin density of
1.1 g/cm3 (, Hecquet et al., 1985, Hecquet et al., 1987,
Gouyette et al., 1986, Holding et al., 1991). In this study,
greater concentrations of >89.8 and 29.5mg/g skin were cal-
culated in 500 and 1500 mm skin layers within 30min.
Though optimal concentrations of topical cisplatin have yet
to be determined in vivo, relative to both preclinical and clin-
ical literature, our findings underscore the feasibility of
achieving high therapeutic levels of drug throughout skin
using AFL.
For hydrophilic drugs, impact of LADD has been shown to
depend on laser channel density and depth. Increasing MAZ
depth is reported to enhance topical delivery of a range of
compounds, including anticancer agents (Wenande et al.,
2017a). This depth-dependence is theorized to be a reflection
of improved hydrophilic drug partitioning from (1) vehicle
into the more hydrophilic medium occupying channels
shortly after irradiation and (2) from the medium into the
surrounding skin tissue (Erlendsson et al., 2016). While
increased transdermal cisplatin permeation and a tendency
towards greater uptake in the deepest skin layer using MAZ-
DD was observed in this study, differences in cutaneous
deposition between MAZ-MD and MAZ-DD did not reach
significance despite the drug’s negative Log P. A potential
explanation may be cisplatin’s sparing water-solubility
(0.253 g/100ml), which could limit the drug’s ability to take
advantage of deeper channels (O’Neil, 2006). Our data also
reveals uniform dermal drug distribution in the 520mm lat-
eral spaces between laser channels, and cisplatin diffusion
from MAZs may saturate in the absence of a strong drug
concentration gradient. It follows, that increasing laser chan-
nel depth beyond a certain threshold may not necessarily
provide further enhancement in drug delivery. Indicating the
possibility of a non-linear relationship between MAZ depth
and drug uptake, we recently showed that increasing MAZ
depth from 104, 322, to 565 mm did not lead to comparable
degrees of enhancement in 5-FU deposition in ex vivo skin
(Wenande et al., 2017b). The current study’s results support
this theory, as differences in skin uptake using 620 vs.
912 mm channel depths were even lower. Whether the same
relationship between channel depth and drug uptake exists
under in vivo conditions remains unexamined.
Early toxicological studies describe cisplatin as a mild skin
irritant following 24-h topical exposure (INCHEM, 1991).
Using the same 1mg/mL cisplatin solution as applied here,
normal appearances of in vivo porcine and murine skin are
reported after simple topical application for 1–12 h
(Miatmoko et al., 2015, Wenande et al., 2018). Delivered by
AFL however, the agent’s safety profile differs due enhanced
skin uptake. We previously assessed this in healthy skin of
live pigs. After 60 mins topical AFL-assisted cisplatin,
increased erythema scores were observed over 5 days versus
AFL alone. Meanwhile, cisplatin remained undetectable in
plasma measured from 0–120 hours, despite >100 cm2 skin
exposures (Wenande et al., 2018). Though additional studies
are needed, risks of AFL-assisted cisplatin therapy thus far
appear acceptable.
The study has limitations. While illustrative and widely
accepted, data derived from ex vivo porcine skin and an
infinite dose model cannot be directly extrapolated to the
clinical setting. ICP-MS relies on detection of Pt rather than
the intact cisplatin molecule, thereby providing an assess-
ment of total skin deposition as opposed to activated or
DNA-bound intracellular species. Though high chloride con-
centrations in the cisplatin solution and cutaneous extracellu-
lar environment theoretically reduce ‘off target’ binding of
cisplatin prior to entering cells, the presence of nucleophilic
elements in skin structures might result in extracellular reten-
tion of cisplatin. For example, sulfur groups associated with
keratin or proteoglycans in skin, could potentially bind the
drug after uptake. However, we found no correlation
between cutaneous distribution of cisplatin and sulfur-rich
skin structures (Figure 4). However, Chang et al. (2016)
recently detected extensive cisplatin binding to dermal colla-
gen four hours post intraperitoneal administration, after
which the drug was slowly released over 7 days (Chang
et al., 2016). Binding and subsequent release of cisplatin
from the dermal extracellular matrix may actually be an
advantage, due to sustained dermal drug availability to cells.
Past studies interestingly indicate that up to 10% of the
activity of released platinum species is retained (Brouwers
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et al., 2008). At present, further investigation is needed to
examine whether cutaneous cisplatin retention results in
reduced treatment efficacy or leads to gradual release of the
drug to adjacent NMSC cells over time.
In conclusion, illustrated by quantitative and semi-quanti-
tative bioimaging analyses, this study demonstrates that AFL
provides rapid, greatly increased and uniform delivery of the
anticancer agent cisplatin deep into full thickness skin.
Improved cutaneous uptake of this potent chemotherapeutic
may prove useful in the development of a new, local and
minimally-invasive treatment for dermatological neoplasms.
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